



ABN 53 075 582 740

ASX ANNOUNCEMENT

1 October 2020

Bionomics Limited Completes Despatch of Retail Entitlement Offer Booklet

On 24 September 2020, Bionomics Limited (ASX: BNO) (**Bionomics** or **Company**), a clinical stage biopharmaceutical company, announced an accelerated pro rata non-renounceable 1:12.54 entitlement offer of new fully paid ordinary shares in the Company (**New Shares**) to raise approximately A\$2,173,320 (before costs) (**Entitlement Offer** or **Equity Raising**).

Bionomics is pleased to announce that it has completed the despatch of the retail offer booklet and personalised entitlement and acceptance form to Bionomics shareholders eligible to participate in the retail component of the Entitlement Offer (**Retail Offer Booklet**).

In addition, a letter to ineligible shareholders will also be dispatched today.

Further information

Further details of the Equity Raising are set out in the Retail Offer Booklet (including the Investor Presentation included in that Retail Offer Booklet) provided to the ASX today.

Retail investor enquiries

If you have any questions in relation to the Equity Raising, please contact the Bionomics Offer Information Line on 1300 556 161 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30 am and 5.00 pm (Adelaide time) Monday to Friday.

Nothing contained in this announcement constitutes investment, legal, tax or other advice. You should make your own assessment and consult your independent broker, solicitor, accountant, financial adviser, or other professional adviser in relation to the information in this announcement and any action to be taken on the basis of that information.

AUTHORISED BY THE COMPANY SECRETARY

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
Bionomics Limited
31 Dalglish St,
Thebarton, South Australia
+61 8 8354 6100
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB:BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. Neither the entitlements nor the New Shares to be offered and sold in the Entitlement Offer have been, or will be, registered under the U.S. Securities Act of 1933 (U.S. Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be exercised or taken up by, and the New Shares may not be offered or sold, directly or indirectly, to, persons in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities law of any state or other jurisdiction of the United States.